Skip to content
Alpha Edge Investing

Alpha Edge Investing

"Investors operate with limited funds and limited intelligence, they don’t need to know everything. As long as they understand better than others, they have an edge.” – George Soros

  • Home
  • Earnings Updates/ Corporate Actions
  • Research – Equities
  • Research – Fixed Income/ Bonds
  • Research – Unit Trust/ ETF
  • News
  • My Opinions/ Views
  • Others
  • About Me
  • Contact
  • Disclaimer
  • Community and Support Forums
  • Toggle search form

KGI: Sinopharm Group Co., Ltd. (1099 HK) – A defensive counter amidst a market downturn

Posted on July 20, 2022July 20, 2022 By alanyeo No Comments on KGI: Sinopharm Group Co., Ltd. (1099 HK) – A defensive counter amidst a market downturn
  • BUY Entry – 17.5 Target – 19.5 Stop Loss – 16.5
  • Sinopharm Group Co Ltd is a China-based company principally engaged in pharmaceutical and medical devices distribution business. The Company operates its business through four segments. Pharmaceutical Distribution segment is engaged in the distribution of pharmaceutical products to hospitals, other distributors, retail pharmacy stores and clinics. Medical Devices segment is engaged in the distribution of medical devices, as well as provides installation and maintenance services. Retail Pharmacy segment is engaged in the operation of chain pharmacy stores. Other Business segment is engaged in the distribution of laboratory supplies, manufacture and distribution of chemical reagents, production and sale of pharmaceutical products.
  • 1Q22 earnings review. 1Q22 revenue grew by 6.86% YoY to RMB17.15bn. Net profit attributable to shareholders dropped by 23.25% YoY to RMB252.36mn. The decrease in profit was mainly attributable to the decline in the results of Sinopharm Accord’s associates due to the impact of the Covid-19 pandemic, which resulted in a corresponding decrease in investment income of Sinopharm Accord. At the same time, due to the impact of the pandemic, the retail sector has seen a decline in store traffic, and the new stores opened in 2021 cost a large initial investment, the benefits of which have not yet emerged, resulting in a decrease in the margin levels.
  • A defensive stock amidst a market downturn. The Hong Kong market has been hammered by both a slowdown in China’s economy and geopolitical risks. Growth, value, and cyclical sectors, as well as other thematic stocks, have been sold off indiscriminately. However, this stock is relatively outperforming the rest as its business is largely immune to inflation and policy risks. The business driver is the distribution volume rather than profit margins. The growth in demand for medicines and medical devices is stable with low price sensitivity.
  • The updated market consensus of the EPS growth in FY22/23 is -0.6%/9.9% YoY respectively, which translates to 5.8x/5.3x forward PE. The current PER is 8.3x. The FY22F/23F dividend yield is 5.2%/5.7%. Bloomberg consensus average 12-month target price is HK$23.37.

(Source: Bloomberg)

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
Research - Equities Tags:Sinopharm

Post navigation

Previous Post: KGI: CapitaLand Integrated Commercial Trust (CICT SP) – Position for strong set of results on 28 July
Next Post: KGI: Nexteer Automotive Group Ltd (1316 HK) – Riding on the auto sector recovery 

Related Posts

UOBKH: China Strategy Research - Equities
DBS: China Healthcare Sector – Pharmaceutical Packaging Research - Equities
DBS: SINOPHARM GROUP CO LTD – Buy Target Price HK$30.00 Research - Equities
DBS: China Biotech Sector Research - Equities
KGI: Sinopharm Group Co., Ltd. (1099 HK) – A defensive counter amidst sell-off Research - Equities
UOBKH: Sinopharm Group – SELL TP HK$15.00 Research - Equities
KGI: Sinopharm Group Co., Ltd. (1099 HK) – One of the few defensive plays Research - Equities

Leave a Reply

You must be logged in to post a comment.

Login

Log In
Register Lost Password
Get new posts by email
Chat on WhatsApp
  • Earnings Updates/ Corporate Actions
  • My Opinions/ Views
  • News
  • Others
  • Research – Equities
  • Research – Fixed Income/ Bonds
  • Research – Unit Trusts/ ETF

Copyright © 2023 Alpha Edge Investing.

Powered by PressBook Grid Blogs theme